BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laharie D, Chanteloup E, Chabrun E, Subtil C, Kowo M, El Hanafi K, DE Lédinghen V. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders. Aliment Pharmacol Ther. 2009;29:1240-1248. [PMID: 19416134 DOI: 10.1111/j.1365-2036.2009.03997.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Ben-horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Letters to the Editors 2012;35:714-22. [DOI: 10.1111/j.1365-2036.2012.04997.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
2 Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn’s disease: A retrospective study. Dig Liver Dis. 2014;46:695-700. [PMID: 24893686 DOI: 10.1016/j.dld.2014.04.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
3 Turner D, Koletzko S, Griffiths AM, Hyams J, Dubinsky M, de Ridder L, Escher J, Lionetti P, Cucchiara S, Lentze MJ, Koletzko B, van Rheenen P, Russell RK, Mack D, Veereman G, Vermeire S, Ruemmele F. Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network. Journal of Pediatric Gastroenterology & Nutrition 2016;62:183-7. [DOI: 10.1097/mpg.0000000000001024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
4 Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 2010;107:222-7. [PMID: 20018674 DOI: 10.1073/pnas.0912937107] [Cited by in Crossref: 116] [Cited by in F6Publishing: 102] [Article Influence: 8.9] [Reference Citation Analysis]
5 Louis E, Mary J, Vernier–massouille G, Grimaud J, Bouhnik Y, Laharie D, Dupas J, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel J, Lemann M. Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped. Gastroenterology 2012;142:63-70.e5. [DOI: 10.1053/j.gastro.2011.09.034] [Cited by in Crossref: 396] [Cited by in F6Publishing: 351] [Article Influence: 39.6] [Reference Citation Analysis]
6 Yang S, Yang S, Kwon Jo Y, Kim S, Jung Chang M, Choi J, Hee Cheon J, Yu YM. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021;12:20406223211041927. [PMID: 34729142 DOI: 10.1177/20406223211041927] [Reference Citation Analysis]
7 Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol 2015; 21(16): 4773-4778 [PMID: 25944990 DOI: 10.3748/wjg.v21.i16.4773] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
8 Brandse JF, Peters CP, Gecse KB, Eshuis EJ, Jansen JM, Tuynman HA, Löwenberg M, Ponsioen CY, van den Brink GR, Dʼhaens GR. Effects of Infliximab Retreatment After Consecutive Discontinuation of Infliximab and Adalimumab in Refractory Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:251-8. [DOI: 10.1097/01.mib.0000438248.14218.1d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]